country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-144338

Copy Link Print Information

PARP1/BRD4-IN-1

PARP1/BRD4-IN-1 is a potent and high selective PARP1/BRD4 inhibitor (IC₅₀s of 49 and 202 nM in PARP1 and BRD4, respectively). PARP1/BRD4-IN-1 represses the expression and activity of PARP1 and BRD4 to synergistically inhibit the malignant growth of pancreatic cancer cells.

For research use only. We do not sell to patients.

CAS No.: 2758117-74-5
Formula: C₂₉H₂₆N₆O₃
Molecular Weight:506.56

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (277 KB)

PARP1/BRD4-IN-1 Chemical Structure

CAS No.: 2758117-74-5

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target

BRD4

202 nM (IC₅₀)

PARP1

49 nM (IC₅₀)

All Epigenetic Reader Domain Isoforms :

All PARP Isoforms :

All DNA/RNA Synthesis Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
CAPAN-1	IC₅₀	0.17 μM Compound: III-7	Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell growth measured after 7 days by MTT assay Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell growth measured after 7 days by MTT assay	[PMID: 35091172]
CAPAN-1	IC₅₀	0.41 μM Compound: III-7	Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell growth measured after 5 days by MTT assay Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell growth measured after 5 days by MTT assay	[PMID: 35091172]
CAPAN-1	IC₅₀	1.71 μM Compound: III-7	Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell growth measured after 4 days by MTT assay Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell growth measured after 4 days by MTT assay	[PMID: 35091172]
CAPAN-1	IC₅₀	7.21 μM Compound: III-7	Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell growth measured after 3 days by MTT assay Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell growth measured after 3 days by MTT assay	[PMID: 35091172]
CFPAC-1	IC₅₀	0.21 μM Compound: III-7	Antiproliferative activity against human CFPAC-1 cells assessed as inhibition of cell growth measured after 7 days by MTT assay Antiproliferative activity against human CFPAC-1 cells assessed as inhibition of cell growth measured after 7 days by MTT assay	[PMID: 35091172]
CFPAC-1	IC₅₀	0.98 μM Compound: III-7	Antiproliferative activity against human CFPAC-1 cells assessed as inhibition of cell growth measured after 5 days by MTT assay Antiproliferative activity against human CFPAC-1 cells assessed as inhibition of cell growth measured after 5 days by MTT assay	[PMID: 35091172]
CFPAC-1	IC₅₀	1.31 μM Compound: III-7	Antiproliferative activity against human CFPAC-1 cells assessed as inhibition of cell growth measured after 4 days by MTT assay Antiproliferative activity against human CFPAC-1 cells assessed as inhibition of cell growth measured after 4 days by MTT assay	[PMID: 35091172]
CFPAC-1	IC₅₀	2.43 μM Compound: III-7	Antiproliferative activity against human CFPAC-1 cells assessed as inhibition of cell growth measured after 3 days by MTT assay Antiproliferative activity against human CFPAC-1 cells assessed as inhibition of cell growth measured after 3 days by MTT assay	[PMID: 35091172]
HCT-116	IC₅₀	1.44 μM Compound: III-7	Antiproliferative activity against BRCA2-mutated human HCT-116 cells assessed as inhibition of cell growth measured after 7 days by MTT assay Antiproliferative activity against BRCA2-mutated human HCT-116 cells assessed as inhibition of cell growth measured after 7 days by MTT assay	[PMID: 35091172]
MDA-MB-231	IC₅₀	0.14 μM Compound: III-7	Antiproliferative activity against BRCA-proficient human MDA-MB-231 cells assessed as inhibition of cell growth measured after 7 days by MTT assay Antiproliferative activity against BRCA-proficient human MDA-MB-231 cells assessed as inhibition of cell growth measured after 7 days by MTT assay	[PMID: 35091172]
MDA-MB-468	IC₅₀	0.09 μM Compound: III-7	Antiproliferative activity against BRCA-proficient human MDA-MB-468 cells assessed as inhibition of cell growth measured after 7 days by MTT assay Antiproliferative activity against BRCA-proficient human MDA-MB-468 cells assessed as inhibition of cell growth measured after 7 days by MTT assay	[PMID: 35091172]
SW1990	IC₅₀	0.56 μM Compound: III-7	Antiproliferative activity against human SW1990 cells assessed as inhibition of cell growth measured after 7 days by MTT assay Antiproliferative activity against human SW1990 cells assessed as inhibition of cell growth measured after 7 days by MTT assay	[PMID: 35091172]
SW1990	IC₅₀	0.98 μM Compound: III-7	Antiproliferative activity against human SW1990 cells assessed as inhibition of cell growth measured after 5 days by MTT assay Antiproliferative activity against human SW1990 cells assessed as inhibition of cell growth measured after 5 days by MTT assay	[PMID: 35091172]
SW1990	IC₅₀	1.34 μM Compound: III-7	Antiproliferative activity against human SW1990 cells assessed as inhibition of cell growth measured after 4 days by MTT assay Antiproliferative activity against human SW1990 cells assessed as inhibition of cell growth measured after 4 days by MTT assay	[PMID: 35091172]
SW1990	IC₅₀	11.71 μM Compound: III-7	Antiproliferative activity against human SW1990 cells assessed as inhibition of cell growth after 3 days by MTT assay Antiproliferative activity against human SW1990 cells assessed as inhibition of cell growth after 3 days by MTT assay	[PMID: 35091172]
THP-1	IC₅₀	0.43 μM Compound: III-7	Antiproliferative activity against human THP-1 cells expressing BRD4 assessed as inhibition of cell growth measured after 3 days by MTT assay Antiproliferative activity against human THP-1 cells expressing BRD4 assessed as inhibition of cell growth measured after 3 days by MTT assay	[PMID: 35091172]

In Vitro

PARP1/BRD4-IN-1 (compound III-7) (0-2 μM; 3-7 days) has potent inhibition of the growth of cancer cell lines^[1].
PARP1/BRD4-IN-1 (0, 1, 2 μM; 4 days) can significantly inhibit the expression of PARP1 and BRD4 at 2 μM in SW1990 cells^[1].
PARP1/BRD4-IN-1 (1, 2 μM; 4 days) arrests the cell cycle at G₀/G₁ and G₂/M phase in SW1990 cells^[1].
PARP1/BRD4-IN-1 (0, 1, 2 μM; 4 days) has the potent efficacy on the apoptosis of SW1990 cells at 2 μM^[1].
PARP1/BRD4-IN-1 (1, 2 μM; 4 days) regulates the expression of HEXIM1, c-Myc, FOXO1, MDC1 and TOPBP1 to enhance the inhibition of DNA repair in SW1990 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line:

CFPAC-1, SW1990, MDA-MB-231, MDA-MB-468, HCT-116, THP-1^[1]
Concentration:

0-2 μM
Incubation Time:

3, 4 or 7 days
Result:

Showed potent inhibition of the growth of cancer cell lines.

Western Blot Analysis

Cell Line:

SW1990^[1]
Concentration:

0, 1, 2 μM
Incubation Time:

4 days
Result:

Significantly inhibited the expression of PARP1 and BRD4 at 2 μM.

Cell Cycle Analysis

Cell Line:

SW1990^[1]
Concentration:

1, 2 μM
Incubation Time:

4 days
Result:

Arrested the cell cycle at G₀/G₁ and G₂/M phase.

Apoptosis Analysis

Cell Line:

SW1990^[1]
Concentration:

0, 1, 2 μM
Incubation Time:

4 days
Result:

Showed potent efficacy on the apoptosis of SW1990 cells at 2 μM.

In Vivo

PARP1/BRD4-IN-1 (30mg/kg; intraperitoneal injection for 28 days) can significantly inhibit the tumor size and weight, and does not cause significant damage of the kidney, lung, spleen, liver and heart in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Athymic nude mice (6-7 weeks, 18-20 g, SW1990-injected)^[1]
Dosage:

30mg/kg
Administration:

Intraperitoneal injection for 28 days
Result:

Significantly inhibited the tumor size and weight and did not cause significant damage of the kidney, lung, spleen, liver and heart.

Chemical Information

CAS No. 2758117-74-5
Molecular Weight 506.56
Formula C₂₉H₂₆N₆O₃
SMILES

O=C(C1=CC=CC2=C1NC(CN3C(N(C)C4=CC=C(C5=C(C)ON=C5C)C=C4C3C6=CC=CC=C6)=O)=N2)N
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Huang SH, et al. Design, synthesis and mechanism studies of novel dual PARP1/BRD4 inhibitors against pancreatic cancer. Eur J Med Chem. 2022;230:114116. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

100 mg

Get Quote In-stock

Amount: USD 0.00

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Purity & Documentation
References

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

PARP1/BRD4-IN-1

All Epigenetic Reader Domain Isoforms

All PARP Isoforms

All DNA/RNA Synthesis Isoforms